FENGYUAN PHARMACEUTICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 100 million yuan, a year-on-year decrease of 31.92%

According to the Zhitong Finance APP, FENGYUAN PHARMACEUTICAL released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 3.125 billion yuan, a year-on-year decrease of 4.18%. The net profit attributable to shareholders of the listed company was 100 million yuan, a year-on-year decrease of 31.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.9151 million yuan, a year-on-year decrease of 36.39%

Zhitong A-share lock-up release overview | October 13

On October 13th, 29 listed companies will have their restricted shares unlocked, with a total market value of approximately 44.553 billion yuan. The unlocking situation includes several companies such as CMPort, FENGYUAN PHARMACEUTICAL, and NFC, involving various types of restricted shares such as additional A-shares and equity incentives. For specific details on the number and types of unlocked shares, please refer to the relevant company information

FENGYUAN PHARMACEUTICAL: The transfer of part of the company's shares by the controlling shareholder and its concerted parties has been completed

FENGYUAN PHARMACEUTICAL announced that its controlling shareholder, FENGYUAN Group, and its concerted party, Ma'anshan FENGYUAN, have completed the transfer of 23,698,600 shares to Hainan Guihe Dayi Investment Partnership, accounting for 5.1% of the total share capital. The transfer price was 6.72 yuan per share, with a total payment of 159 million yuan. After the transfer, FENGYUAN Group and its concerted party's shareholding decreased to 109 million shares, accounting for 23.51% of the total share capital. Guihe Dayi has become the third-largest shareholder and has committed not to reduce its holdings within eighteen months

FENGYUAN PHARMACEUTICAL's controlling shareholder plans to transfer 5.1% of its shares, which will not affect control

Anhui FENGYUAN PHARMACEUTICAL's controlling shareholder FENGYUAN Group and its concerted actor Ma'anshan FENGYUAN intend to transfer 23,698,554 shares, accounting for 5.10% of the total share capital, to Hainan Guihe Dayi, at a transfer price of 6.72 yuan/share, totaling 159 million yuan. This transaction does not affect the company's control and does not involve a tender offer or related party transactions, but it requires compliance review by the Shenzhen Stock Exchange, and the final completion is uncertain

Pharmaceutical and medical stocks continue to strengthen, with FENGYUAN PHARMACEUTICAL hitting the limit up, Hengrui Pharma rising over 7%, and Haisco, BIOCAUSE HEILEN PHARMA, Yatai pharm, and Yirui Biologics also following suit